HOWL Surges on Ambros Merger, Eyes CRPS Treatment

Werewolf Therapeutics (HOWL) saw its shares more than double on Friday, August 21, 2026, following the announcement of a definitive merger agreement with privately held Ambros Therapeutics. This transaction is set to significantly reshape the company's strategic direction.

Upon completion, the merged entity will prioritize Ambros's neridronate program, currently in pivotal Phase 3 trials for CRPS-1. Neridronate has already garnered FDA designations, including Breakthrough Therapy, Fast Track, and Orphan Drug status.

The merger also brings substantial financial backing, with investors committing $150 million through a PIPE financing. This funding is expected to sustain the combined company through the CRPS-RISE Phase 3 results and a planned New Drug Application submission.

While the merger optimism has driven a significant stock rally, the long-term outlook hinges on neridronate's success. CRPS-RISE Phase 3 results are anticipated in 2028, with neridronate potentially becoming the first FDA-approved therapy for CRPS-1, a condition affecting an estimated 65,000 new U.S. patients annually.

However, investors should note the considerable dilution. Existing HOWL shareholders are projected to own approximately 6.8% of the combined entity, with Ambros holders receiving 71.7% and PIPE investors 21.5%. Future stock performance will likely depend on clinical progress rather than the merger announcement itself.